DSNKY:OTC-Daiichi Sankyo Co Ltd ADR (USD)

COMMON STOCK | Drug Manufacturers - General |

Last Closing

USD 32.24

Change

0.00 (0.00)%

Market Cap

USD 63.77B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-10-04 )

Largest Industry Peers for Drug Manufacturers - General

Symbol Name Price(Change) Market Cap
RHHBY Roche Holding Ltd ADR

N/A

USD 258.74B
RHHVF Roche Holding AG Participation

-6.28 (-2.05%)

USD 258.74B
RHHBF Roche Holding AG

N/A

USD 258.74B
AZNCF AstraZeneca PLC

-0.14 (-0.09%)

USD 241.92B
SNYNF Sanofi

N/A

USD 142.76B
CHGCY Chugai Pharmaceutical Co Ltd A..

-0.12 (-0.51%)

USD 83.22B
ALPMF Astellas Pharma Inc

N/A

USD 21.46B
ALPMY Astellas Pharma Inc

N/A

USD 21.25B
RICFY Recordati Industria Chimica e ..

N/A

USD 11.87B
KYKOF Kyowa Kirin Co. Ltd

N/A

USD 11.02B

ETFs Containing DSNKY

1638:TSE 13.34 % 0.00 %

N/A

N/A
JPCHBH:SW 1.58 % 0.00 %

N/A

N/A
JPUSBH:SW 1.58 % 0.00 %

N/A

N/A
JPEUBH:SW 1.57 % 0.00 %

N/A

N/A
UEF2:F 1.36 % 0.00 %

N/A

N/A
UEF2:XETRA 1.36 % 0.00 %

N/A

N/A
EJAH:F BNP Paribas Easy - MSCI J.. 0.00 % 0.00 %

+0.04 (+0%)

N/A
SXR6:F iShares MSCI Japan SRI UC.. 0.00 % 0.00 %

+0.11 (+0%)

USD 1.03B
JSRI:XETRA BNP Paribas Easy MSCI Jap.. 0.00 % 0.00 %

+0.26 (+0%)

USD 0.44B
1473:TSE DIAM TOPIX 0.00 % 0.00 %

-1.00 (0%)

USD 583.54B
1474:TSE DIAM JPX Nikkei 400 0.00 % 0.00 %

+110.00 (+0%)

USD 284.09B
1498:TSE AM-One ESG 0.00 % 0.00 %

+105.00 (+0%)

USD 10.48B
1596:TSE 0.00 % 0.00 %

N/A

N/A
NADA:XETRA Lyxor Core MSCI Japan (DR.. 0.00 % 0.00 %

+0.97 (+0%)

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - General) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.88% 76% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.88% 74% C 68% D+
Trailing 12 Months  
Capital Gain 20.70% 76% C+ 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.70% 74% C 66% D+
Trailing 5 Years  
Capital Gain 55.30% 91% A- 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.30% 79% B- 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 10.25% N/A N/A 54% F
Dividend Return 10.25% N/A N/A 51% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 28.53% N/A N/A 74% C
Risk Adjusted Return 35.91% N/A N/A 72% C
Market Capitalization 63.77B 70% C- 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Underpriced on cashflow basis

The stock is trading low compared to its peers on a price to cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.